Published in Thromb Haemost on September 26, 2012
Molecular approaches for improved clotting factors for hemophilia. Blood (2013) 0.85
Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia (2013) 0.79
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. J Pharm Sci (2014) 0.79
Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus (2014) 0.77
Learn more to do better... even for participants in haemophilia clinical trials. Blood Transfus (2015) 0.75
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica (2009) 3.63
Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med (2010) 3.20
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood (2007) 3.15
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet (2009) 3.00
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood (2008) 2.97
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005) 2.75
First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol (2009) 2.71
Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol (2006) 2.70
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Venous thromboembolism--a manifestation of the metabolic syndrome. Haematologica (2007) 2.49
Prediction of venous thromboembolism in cancer patients. Blood (2010) 2.31
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood (2008) 2.17
Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol (2005) 2.06
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res (2005) 1.97
The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). IEEE Trans Med Imaging (2014) 1.91
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg (2008) 1.85
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood (2013) 1.84
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2009) 1.78
Lung endothelial heparan sulfates mediate cationic peptide-induced barrier dysfunction: a new role for the glycocalyx. Am J Physiol Lung Cell Mol Physiol (2003) 1.76
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol (2005) 1.73
Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med (2009) 1.69
Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke (2002) 1.64
High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica (2012) 1.62
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology (2011) 1.61
[The Club of Female Professors of the Medical University Vienna]. Wien Med Wochenschr (2009) 1.60
Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol (2004) 1.58
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology (2002) 1.57
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol (2012) 1.56
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer (2004) 1.55
Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. Ann Allergy Asthma Immunol (2010) 1.55
Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. Arch Surg (2010) 1.52
Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol (2011) 1.51
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood (2012) 1.50
Diagnostic performance and therapeutic consequence of thromboelastometry activated by kaolin versus a panel of specific reagents. Anesthesiology (2011) 1.48
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs (2006) 1.46
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer (2004) 1.45
A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med (2013) 1.42
Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. Br J Haematol (2008) 1.41
Anticoagulant therapy in oncologic patients undergoing venous stenting for superior vena cava syndrome and other interventional procedures. Cardiovasc Intervent Radiol (2014) 1.38
Microscopic examination of bone marrow aspirates in malignant disorders of haematopoiesis--a comparison of two slide preparation techniques. Ann Hematol (2011) 1.38
Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes (2010) 1.36
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol (2009) 1.36
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker. Acad Radiol (2010) 1.35
High homocysteine and thrombosis without connective tissue disorders are associated with a novel class of cystathionine beta-synthase (CBS) mutations. Hum Mutat (2002) 1.29
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer (2006) 1.21
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res (2007) 1.20
Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost (2015) 1.20
Femoral head blood flow reduction and hypercoagulability under 24 h megadose steroid treatment in pigs. J Orthop Res (2004) 1.19
Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol (2011) 1.17
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res (2005) 1.17
Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol (2006) 1.16
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol (2012) 1.15
The use of volumetric CT as an imaging biomarker in lung cancer. Acad Radiol (2010) 1.15
The postoperative splenic/portal vein thrombosis after splenectomy and its prevention--an unresolved issue. Haematologica (2008) 1.13
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood (2012) 1.11
Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer (2004) 1.10
Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population. Abdom Imaging (2011) 1.10
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood (2012) 1.09
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res (2009) 1.08
Fibrinogen estimates are influenced by methods of measurement and hemodilution with colloid plasma expanders. Transfusion (2010) 1.08
The role of PC-1 and ACE genes in diabetic nephropathy in type 1 diabetic patients: evidence for a polygenic control of kidney disease progression. Nephrol Dial Transplant (2002) 1.08
Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol (2007) 1.07
Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost (2007) 1.04
Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med (2002) 1.03
Rituximab for the treatment of acquired antibodies to factor VIII. Haematologica (2007) 1.03
Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol (2011) 1.02
The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant (2011) 1.02
High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem (2007) 1.01
Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis (2003) 1.00
Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis. Infect Immun (2007) 1.00
Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism. Semin Thromb Hemost (2009) 1.00
Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol (2008) 1.00
Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol (2012) 0.99
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol (2010) 0.99
Impact of prothrombotic mutations and family history on the occurrence of intra-uterine fetal deaths. Haematologica (2002) 0.99
Hepatic intraductal oncocytic papillary carcinoma. Cancer (2002) 0.98
Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol (2010) 0.98
Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol (2012) 0.98
Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol (2006) 0.97
Sex differences in the association of apolipoprotein E and angiotensin-converting enzyme gene polymorphisms with healthy aging and longevity: a population-based study from Southern Italy. J Gerontol A Biol Sci Med Sci (2006) 0.97
Haemophilia A: molecular insights. Clin Chem Lab Med (2007) 0.96
The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica (2006) 0.95
The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg (2006) 0.95
Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation. Proc Natl Acad Sci U S A (2006) 0.94